TITLE:
Intravitreal Faricimab for Uveitic Macular Edema in Vogt-Koyanagi-Harada Syndrome: A Case Report
AUTHORS:
Francisco Dacarett, Juan Pablo Handal, Angélica Núñez, Diana Rosales
KEYWORDS:
Vogt-Koyanagi-Harada Syndrome, Faricimab, Uveitic Macular Edema, Angiopoietin-2, Corticosteroids, Dual Inhibition
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.16 No.4,
November
17,
2026
ABSTRACT: Vogt-Koyanagi-Harada (VKH) syndrome is a multisystem autoimmune disease in which uveitic macular edema (UME) represents a major cause of vision loss during chronic stages. We present the case of a 32-year-old Hispanic woman with a 10-year history of chronic VKH who presented with acute blurred vision, tinnitus, and headaches. Clinical evaluation revealed localized cystoid macular edema in the left eye with a central subfield thickness (CST) of 325 µm, loss of foveal depression, and best-corrected visual acuity (BCVA) of 20/150 in the left eye. Fluorescein angiography and anterior segment examination confirmed active inflammation localized strictly to the left macula without acute panuveitic flare. A single intravitreal injection of Faricimab (6.0 mg/0.05 mL) was administered on November 4, 2025, concurrently with a low-frequency topical corticosteroid regimen (prednisolone acetate 1.0%/phenylephrine 0.12%). One month post-injection, complete resolution of cystoid macular edema was observed, with CST decreasing to 163 µm, restoration of the normal foveal contour, and BCVA improvement to 20/50 in the left eye. No intraocular inflammation, intraocular pressure elevation, or adverse events occurred. While rapid anatomical and functional improvement was observed following faricimab administration with concurrent topical corticosteroid therapy, this uncontrolled observation cannot establish faricimab’s independent efficacy or steroid-sparing capacity. Dual VEGF/Ang-2 inhibition represents a promising adjunct for localized uveitic macular edema, but prospective controlled studies are required to define its independent role.